Inogen is expected to report Q3 2026 revenue of $82.26 million and a net loss of $0.46 per share, with the current $14.58 stock price trading at a significant premium to the $12.25 average analyst price target.
Investors are primarily focused on the growth trajectory of rental revenue as the company shifts its focus toward higher-margin recurring income streams.
The medical device manufacturer has faced persistent headwinds in its direct-to-consumer segment, making the commercial adoption of the Rove 6 portable concentrator critical for stabilizing the top line. Analysts will also be scrutinizing gross margin improvements and any updates to the full-year 2026 adjusted EBITDA guidance.